2012 CIHR Knowledge Translation prize Congratulations to Dr Peter von Dadelszen “This package is, quite simply, an overwhelmingly impressive account of work of immense quality and far-reaching impact. The work in KT is exemplary in employing sound research methods and in evaluating the impact on health outcomes of the dissemination of the KT materials. This is, quite frankly, an outstanding application.” And, “The letters of nomination…are the strongest letters I have ever read about anyone for any award! They document the incredi- ble national and international impact that Dr von Dadelszen‟s contributions have had to women‟s health around the world, and the tremendous recognition he has received and is receiving.” These were the words of two Canadian Institutes of Health Research (CIHR) reviewers who chose our very own Dr Peter von Dadelszen‟s nomination over 16 others for the prestigious 2012 CIHR Knowledge Translation (KT) Prize of $100,000. The CIHR KT Prize honours and supports the exemplary KT efforts and activities of an exceptional individual, team, or organization that has made an outstanding contribution to increasing the application of research findings, improving the health of individuals, improving health services and products, or strengthening the health-care system. Dr Matthews Mathai, Coordinator for Epidemiology, Monitoring & Evaluation, Maternal & Perinatal Health Depart- ment, WHO and PI for PRE-EMPT Objective 5: KT, nominated Peter. His nomination letter outlines Peter‟s impressive international accomplishments related both to pre-eclampsia basic science and health services research KT activities. He wrote, “How has Peter achieved this remarkable track record of KT with such a broad range of international partners? In my opinion it is his patent knowledge of his topic, his respectful and open manner that invites con- tributions from global partners, and the esteem in which he is held by those partners, that has led to his international pre-eminence in the area of global woman‟s health, and pre-eclampsia especially. You hear his name mentioned everywhere.” The Society of Obstetricians and Gynecologists of Canada (SOGC) also supported Peter‟s nomination. They recognized Peter‟s pioneering achievements in development of the PIERS predictive models, co-authorship of numerous SOGC clinical practice guidelines, and numerous published strategic KT implementation studies that utilize pre-post implementation designs to measure guideline impact at population levels. What will Peter do with the $100,000 associated with the award? Peter states, “While a personal recognition, in my mind this award recognizes the creativity, immense amount of work, and attention to detail that our group has developed and maintained over the past 12 years. My plan is to use the funds to complete the fullPIERS modelling process (external validation), so that the fullPIERS model can be used to improve maternal and perinatal health outcomes interna- tionally. Through new and existing international partnerships, we will leverage these funds to create a fully powered fullPIERS validation data set, externally validate the existing model, and, if appropriate, recalibrate the fullPIERS model.” miniPIERS has been developed and validated as the primary focus of PRE-EMPT Objective 2.The PRE-EMPT and global pre-eclampsia community extend their warmest congratulations to Peter. We have all witnessed his com- mitment, service, personal sacrifice, time away from his family, and unending devotion to the cause of alleviating the global burden of pre-eclampsia. We also extend our gratitude to the CIHR for this award in recognition of Peter‟s ex- traordinary achievements and contributions. Dr. Diane Sawchuck, RN, PhD PRE-EMPT N EWSLETTER : I SSUE 6; S EPT ., 2012 PRE-EMPT News The logo focuses on the current WHO data on maternal mortality ratios in Africa and South Asia Recent Activity The PRE-EMPT newsletter is designed for those involved in this project. We hope this publication will keep you up to date on current and upcoming activities, important project changes and accom- plishments by the team. The newsletter will be distributed bimonthly, with the next issue scheduled for the end of No- vember. We welcome submissions of project updates by any team member for inclusion in the newsletter. Please sub- WHO Working Group Meeting on Maternal Mortality & Morbidity, Montreux, Switzerland August 28-31 Global Pregnancy CoLaboratory Second Annual Meeting, Oriel College, Oxford, United Kingdom September 3-6 Members at the Annual Global Pregnancy Colaboraotry meeting, Page.3
4
Embed
PRE-EMPT NEWSLETTER: ISSUE 6; SEPT., 2012 Newsletter... · coffee mugs to acknowledge the contribution of antenatal ... discussions focused on pre-eclampsia screening and triggers
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
2012 CIHR Knowledge Translation prize
Congratulations to Dr Peter von Dadelszen
“This package is, quite simply, an overwhelmingly impressive account of
work of immense quality and far-reaching impact. The work in KT is exemplary
in employing sound research methods and in evaluating the impact on health
outcomes of the dissemination of the KT materials. This is, quite frankly, an
outstanding application.” And, “The letters of nomination…are the strongest
letters I have ever read about anyone for any award! They document the incredi-
ble national and international impact that Dr von Dadelszen‟s contributions
have had to women‟s health around the world, and the tremendous recognition
he has received and is receiving.”
These were the words of two Canadian Institutes of Health Research (CIHR)
reviewers who chose our very own Dr Peter von Dadelszen‟s nomination over
16 others for the prestigious 2012 CIHR Knowledge Translation (KT) Prize of
$100,000. The CIHR KT Prize honours and supports the exemplary KT efforts
and activities of an exceptional individual, team, or organization that has made
an outstanding contribution to increasing the application of research findings,
improving the health of individuals, improving health services and products, or
strengthening the health-care system. Dr Matthews Mathai, Coordinator for
Epidemiology, Monitoring & Evaluation, Maternal & Perinatal Health Depart-
ment, WHO and PI for PRE-EMPT Objective 5: KT, nominated Peter. His
nomination letter outlines Peter‟s impressive international accomplishments
related both to pre-eclampsia basic science and health services research KT
activities. He wrote, “How has Peter achieved this remarkable track record of
KT with such a broad range of international partners? In my opinion it is his
patent knowledge of his topic, his respectful and open manner that invites con-
tributions from global partners, and the esteem in which he is held by those
partners, that has led to his international pre-eminence in the area of global
woman‟s health, and pre-eclampsia especially. You hear his name mentioned
everywhere.” The Society of Obstetricians and Gynecologists of Canada
(SOGC) also supported Peter‟s nomination. They recognized Peter‟s pioneering
achievements in development of the PIERS predictive models, co-authorship of
numerous SOGC clinical practice guidelines, and numerous published strategic
KT implementation studies that utilize pre-post implementation designs to
measure guideline impact at population levels.
What will Peter do with the $100,000 associated with the award? Peter states,
“While a personal recognition, in my mind this award recognizes the creativity,
immense amount of work, and attention to detail that our group has developed
and maintained over the past 12 years. My plan is to use the funds to complete
the fullPIERS modelling process (external validation), so that the fullPIERS
model can be used to improve maternal and perinatal health outcomes interna-
tionally. Through new and existing international partnerships, we will leverage
these funds to create a fully powered fullPIERS validation data set, externally
validate the existing model, and, if appropriate, recalibrate the fullPIERS
model.” miniPIERS has been developed and validated as the primary focus of
PRE-EMPT Objective 2.The PRE-EMPT and global pre-eclampsia community
extend their warmest congratulations to Peter. We have all witnessed his com-
mitment, service, personal sacrifice, time away from his family, and unending
devotion to the cause of alleviating the global burden of pre-eclampsia. We also
extend our gratitude to the CIHR for this award in recognition of Peter‟s ex-
traordinary achievements and contributions.
Dr. Diane Sawchuck, RN, PhD
PRE-EMPT NEWSLETTER : ISSUE 6 ; SEPT . , 2012
PRE-EMPT News
The logo focuses on the current WHO data on maternal mortality ratios in Africa and
South Asia
Recent Activity
The PRE-EMPT newsletter is designed
for those involved in this project. We
hope this publication will keep you up to
date on current and upcoming activities,
important project changes and accom-
plishments by the team. The newsletter
will be distributed bimonthly, with the
next issue scheduled for the end of No-
vember. We welcome submissions of
project updates by any team member for
inclusion in the newsletter. Please sub-
WHO Working Group
Meeting on Maternal
Mortality & Morbidity,
Montreux, Switzerland
August 28-31
Global Pregnancy
CoLaboratory Second
Annual Meeting, Oriel
College, Oxford, United
Kingdom
September
3-6
Members at the Annual Global Pregnancy
Colaboraotry meeting, Page.3
P R E - E M P T N E W S L E T T E R : I S S U E 6 ; S E P T . , 2 0 1 2 P A G E 2
drafted and is being reviewed by all co-authors.
Next up for the Monitoring group in PRE-EMPT will be to
work on secondary analysis of the PIERS data including assess-
ment of risk factors for perinatal outcomes, development of the
genPIERS model, and more in-depth assessment of site specific
data.
If any collaborator has an idea they think can be tested using the